Enzon Pharmaceuticals Inc  

(Public, OTCMKTS:ENZN)   Watch this stock  
Find more results for ENZN
-0.010 (-3.32%)
Dec 15 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.29 - 0.31
52 week 0.03 - 0.40
Open 0.30
Vol / Avg. 242,377.00/55,055.00
Mkt cap 12.82M
P/E 34.74
Div/yield 0.15
EPS 0.01
Shares 44.21M
Beta 0.90
Inst. own 15%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 101.32% -13.44%
Operating margin -121.85% 79.31%
EBITD margin - 79.96%
Return on average assets 4.97% -6.59%
Return on average equity 5.15% -7.92%
Employees 1 -
CDP Score - -


20 Commerce Drive, Suite 135
United States - Map
+1-732-9804500 (Phone)
+1-302-6555049 (Fax)

Website links


Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn's disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.

Officers and directors

Jonathan N. Christodoro Chairman of the Board
Age: 41
Andrew D. Rackear J.D. Chief Executive Officer, Secretary
Age: 60
Richard L. Feinstein Chief Financial Officer, Vice President - Finance
Age: 71
Odysseas D. Kostas M.D. Director
Age: 40
Jennifer I. McNealey Director
Age: 42